Abetimus
- Generic Name
- Abetimus
- Drug Type
- Biotech
- CAS Number
- 167362-48-3
- Unique Ingredient Identifier
- P3UVQ22SHK
- Background
Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.
- Indication
Investigated for use/treatment in kidney disease and systemic lupus erythematosus.
Study of LJP 394 (Abetimus Sodium) in Lupus Patients
- Conditions
- Systemic Lupus Erythematosus
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Registration Number
- NCT00390091
- Locations
- ๐บ๐ธ
Wallace Rheumatic Study Center, Los Angeles, California, United States
๐บ๐ธAltoona Center for Clinical Research, Duncansville, Pennsylvania, United States
Study of LJP 394 in Lupus Patients With History of Renal Disease
- Conditions
- Lupus Erythematosus, SystemicLupus Nephritis
- Interventions
- Drug: Phosphate-buffered saline
- First Posted Date
- 2004-08-17
- Last Posted Date
- 2009-04-01
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Target Recruit Count
- 943
- Registration Number
- NCT00089804
- Locations
- ๐บ๐ธ
Ohio State University Medical Center, Columbus, Ohio, United States
๐บ๐ธMiami Children's Hospital, Miami, Florida, United States
๐บ๐ธCRIA Research, Fort Lauderdale, Florida, United States
Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease
- Conditions
- Immunologic DiseasesAutoimmune DiseasesSystemic Lupus ErythematosusLupus NephritisLupus Glomerulonephritis
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2006-09-25
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Target Recruit Count
- 330
- Registration Number
- NCT00035308
- Locations
- ๐บ๐ธ
Emory University School of Medicine, Renal Division, Atlanta, Georgia, United States
๐บ๐ธRheumatology Associates, Chicago, Illinois, United States
๐บ๐ธUniversity of Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.